Cargando…

Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy

This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiog...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Cheng, Binglu, Zhao, Gang, Yuan, Hengjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380491/
https://www.ncbi.nlm.nih.gov/pubmed/35379700
http://dx.doi.org/10.1136/jim-2022-002339
_version_ 1784768896733020160
author Liu, Chang
Cheng, Binglu
Zhao, Gang
Yuan, Hengjie
author_facet Liu, Chang
Cheng, Binglu
Zhao, Gang
Yuan, Hengjie
author_sort Liu, Chang
collection PubMed
description This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiogram, ECG, myocardial enzymes and blood biochemical indices before, during and after chemotherapy were studied. SPSS V.20 was used to conduct statistical analysis. The differences in heart rate, ST-segment abnormalities, creatine kinase, lactate dehydrogenase, hemoglobin, albumin, triglycerides and high-density lipoprotein were statistically significant. Heart rate and triglycerides increased significantly in the early stage of chemotherapy; ST-segment abnormality increased during the entire chemotherapy period; creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy; hemoglobin and albumin decreased in the early stage of chemotherapy. The magnitude is large; high-density lipoprotein decreases throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy.
format Online
Article
Text
id pubmed-9380491
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-93804912022-08-30 Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy Liu, Chang Cheng, Binglu Zhao, Gang Yuan, Hengjie J Investig Med Original Research This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiogram, ECG, myocardial enzymes and blood biochemical indices before, during and after chemotherapy were studied. SPSS V.20 was used to conduct statistical analysis. The differences in heart rate, ST-segment abnormalities, creatine kinase, lactate dehydrogenase, hemoglobin, albumin, triglycerides and high-density lipoprotein were statistically significant. Heart rate and triglycerides increased significantly in the early stage of chemotherapy; ST-segment abnormality increased during the entire chemotherapy period; creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy; hemoglobin and albumin decreased in the early stage of chemotherapy. The magnitude is large; high-density lipoprotein decreases throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy. BMJ Publishing Group 2022-08 2022-04-04 /pmc/articles/PMC9380491/ /pubmed/35379700 http://dx.doi.org/10.1136/jim-2022-002339 Text en © American Federation for Medical Research 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Liu, Chang
Cheng, Binglu
Zhao, Gang
Yuan, Hengjie
Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title_full Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title_fullStr Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title_full_unstemmed Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title_short Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
title_sort process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380491/
https://www.ncbi.nlm.nih.gov/pubmed/35379700
http://dx.doi.org/10.1136/jim-2022-002339
work_keys_str_mv AT liuchang processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy
AT chengbinglu processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy
AT zhaogang processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy
AT yuanhengjie processanalysisofanthracyclineadversereactionsinbreastcancerpatientswithpostoperativechemotherapy